Holen Sie sich die Stockscreener-App
27.16
3.48%
-0.98
Handel nachbörslich:
27.17
0.01
+0.04%
Schlusskurs vom Vortag:
$28.14
Offen:
$27.825
24-Stunden-Volumen:
15.67M
Relative Volume:
1.44
Marktkapitalisierung:
$10.57B
Einnahmen:
$3.14B
Nettoeinkommen (Verlust:
$-3.36B
KGV:
-3.1111
EPS:
-8.73
Netto-Cashflow:
$-4.03B
1W Leistung:
+1.57%
1M Leistung:
+5.15%
6M Leistung:
-4.84%
1J Leistung:
-50.04%
1-Tages-Spanne:
$26.86
$27.87
1-Wochen-Bereich:
$24.25
$29.20
52-Wochen-Spanne:
$23.15
$56.70
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Vergleichen Sie MRNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
27.16 | 10.99B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna’s Mysterious Exit Sparks Acquisition Frenzy—What’s Really Happening? - Smartkarma
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - York Dispatch
Y Intercept Hong Kong Ltd Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
Sumitomo Mitsui Trust Group Inc. Trims Holdings in Moderna, Inc. $MRNA - MarketBeat
Asset Management One Co. Ltd. Reduces Stock Position in Moderna, Inc. $MRNA - MarketBeat
How Moderna Inc. stock benefits from tech adoptionJuly 2025 Catalysts & Detailed Earnings Play Strategies - newser.com
Moderna (NASDAQ:MRNA) Stock Price Up 9.5%Time to Buy? - MarketBeat
Moderna Stock Falls, Reversing Some Buyout Rally Gains | 2025News and Statistics - IndexBox
Why Moderna (MRNA) Stock Is Trading Lower Today - Yahoo Finance
Moderna: Focus On Cancer Vaccines, Not Buyout (NASDAQ:MRNA) - Seeking Alpha
Moderna (MRNA) Stock Is Trading Lower Friday: What's Going On? - Benzinga
Moderna (MRNA) Stock Retreats After Acquisition Speculation Surge - GuruFocus
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Strength Seen in Moderna (MRNA): Can Its 13.9% Jump Turn into More Strength? - Nasdaq
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline - sharewise.com
Will Moderna Inc. stock gain from strong economyWeekly Profit Summary & Safe Capital Investment Plans - newser.com
Using Ichimoku Cloud for Moderna Inc. technicalsForecast Cut & Daily Profit Focused Screening - newser.com
Is Moderna Inc. meeting your algorithmic filter criteriaWeekly Trend Summary & Long Hold Capital Preservation Tips - newser.com
Best data tools to analyze Moderna Inc. stockJuly 2025 Sector Moves & Short-Term High Return Ideas - newser.com
Moderna Ignites Biotech Sector with Deal Talk Surge Amidst Broader Healthcare Woes - FinancialContent
S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges - Investopedia
Moderna (MRNA) Stock Rallies on Rumors of Potential Takeover Deal - parameter.io
Moderna Stock Rallies On Reports Of Company Entering Talks With A Drugmaker For A Potential Deal - Stocktwits
Moderna soars after STAT reports “a buyout or a large partnership” are on the table - Sherwood News
Moderna gains on report it held talks with at least one large drugmaker (MRNA:NASDAQ) - Seeking Alpha
Moderna Q2 2025 slides: Revenue falls 41% as company pivots to diversified pipeline - Investing.com
Moderna gains on report it held talks with at least one large drugmaker (update) - MSN
Moderna rises after report on potential deal talks - TradingView
Moderna (MRNA) Considers Potential Buyout in Discussions with Ma - GuruFocus
Moderna (MRNA) Shares Surge Amid Potential Major Deal Talks - GuruFocus
Moderna jumps almost 11% on big deal rumors - breakingthenews.net
Earnings call transcript: Moderna sees Q2 2025 revenue drop, stock surges - Investing.com
Moderna (MRNA) Experiences Notable Increase in Morning Trading - GuruFocus
Applying Wyckoff theory to Moderna Inc. stock2025 Analyst Calls & Smart Allocation Stock Reports - newser.com
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewswire Inc.
How Moderna Inc. stock performs during Fed tightening cyclesJuly 2025 Decliners & Consistent Growth Equity Picks - newser.com
Moderna (MRNA) Projected to Post Earnings on Thursday - MarketBeat
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 - The Marion Star
Moderna Seeks Outside Investors to Fund Select Vaccine Trials - MSN
US health agency fires official who opposed mRNA Covid shots - MarketScreener
New COVID vaccine says it’s for the ‘senior class’ — does it reduce side effects? - San Francisco Chronicle
AlphaQuest LLC Increases Position in Moderna, Inc. $MRNA - MarketBeat
Ethic Inc. Purchases 10,325 Shares of Moderna, Inc. $MRNA - MarketBeat
How Moderna Inc. stock trades before earningsWatch List & Community Verified Swing Trade Signals - newser.com
Will Moderna Inc. stock see insider buyingJuly 2025 Breakouts & Verified Momentum Watchlists - Fundação Cultural do Pará
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - The Times Telegram
Why Moderna Inc. stock is a value investor pick2025 Retail Activity & Stock Portfolio Risk Management - Fundação Cultural do Pará
Vertex and Moderna’s VX-522 Study: A Potential Breakthrough in Cystic Fibrosis Treatment - TipRanks
Moderna Says Vax Efficacy Math Doesn't Show Investor Fraud - Law360
What’s next for Moderna Inc. stock priceJuly 2025 Institutional & High Conviction Buy Zone Picks - newser.com
Is Moderna Inc. stock in correction or buying zone2025 Investor Takeaways & Smart Money Movement Tracker - newser.com
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):